Aptar’s Introduction to INNA-051 Investigational Nasal Spray
AptarGroup a global leader in drug delivery, dosing, and protection technologies, has announced the use of its Unidose (UDS) Powder Nasal Spray System in a Phase II clinical study being conducted by ENA Respiratory. This study focuses on INNA-051, an investigational nasal spray designed to help protect against symptomatic viral respiratory infections. The collaboration highlights the growing importance of innovative intranasal delivery technologies in the development of next-generation, non-vaccine approaches aimed at preventing respiratory illnesses.
The study marks a significant step forward in addressing respiratory infections, which continue to pose a major global health burden. While vaccines have been instrumental in combating many viral diseases, there remains a clear need for complementary solutions that can provide broader, virus-agnostic protection. INNA-051 is being developed as part of this new wave of therapeutic strategies, aiming to enhance the body’s natural defense mechanisms rather than targeting a specific virus.
ENA Respiratory, a clinical-stage pharmaceutical company, is at the forefront of developing antiviral host defense enhancers. These therapies are designed to boost the innate immune response in the respiratory tract, potentially helping to reduce the severity and spread of infections caused by a range of respiratory viruses. The company recently announced that the first participants have been dosed in its Phase II clinical trial of INNA-051, marking an important milestone in its clinical development program.
The Phase II study is designed to evaluate several key parameters, including safety, tolerability, and potential effectiveness. It is a community-based study involving adults who are at increased risk of exposure to viral respiratory infections. By focusing on this population, the study aims to generate meaningful data on how the investigational nasal spray performs in real-world conditions where exposure risk is elevated.
One of the distinguishing features of this study is the once-weekly dosing regimen of INNA-051. This approach could offer a convenient and practical option for individuals seeking ongoing protection against respiratory infections, particularly in high-risk environments. The goal is to assess whether regular use of the nasal spray can reduce the burden of symptomatic illness, thereby contributing to improved public health outcomes.
A critical component of this clinical program is the use of Aptar Pharma’s UDS powder nasal delivery system. This advanced delivery platform has been specifically designed to administer a single, precise dose of dry powder directly into the nasal cavity. Precision dosing is essential in clinical development, as it ensures consistency across participants and helps generate reliable data on the investigational product’s performance.
The UDS system is engineered to provide consistent intranasal delivery, which is particularly important for therapies targeting the upper respiratory tract. By delivering the active compound directly to the site of infection or initial viral entry, intranasal systems like UDS can potentially enhance therapeutic effectiveness while minimizing systemic exposure.
In addition to its precision, the UDS powder nasal delivery system is designed with user convenience in mind. It is a ready-to-use device that simplifies administration, making it suitable for use in both clinical trials and potential real-world applications. Ease of use is a key factor in ensuring patient compliance, especially for preventive therapies that may need to be used regularly.
Another important advantage of the UDS system is its compatibility with dry powder formulations. Dry powders often offer improved stability compared to liquid formulations, which can be sensitive to temperature and require cold-chain storage. By enabling the use of stable powder formulations, the UDS system supports the development of therapies that are easier to store, transport, and distribute.
To further enhance the stability and protection of the formulation, the nasal delivery system is housed within Aptar CSP Technologies’ innovative container closure system. This system incorporates fully integrated 3-Phase Activ-Polymer™ technology, which is specifically designed to protect the powder formulation from moisture. Moisture control is critical for maintaining the integrity and efficacy of dry powder drugs, as exposure to humidity can compromise their performance.
The container closure system also includes several internal design features aimed at ensuring device reliability and patient safety. For example, it is engineered to prevent premature actuation that could occur during handling, insertion, removal, or accidental dropping of the device. This helps ensure that the full dose is delivered only when intended, thereby supporting accurate and effective treatment.
The collaboration between Aptar Pharma and ENA Respiratory underscores the importance of integrating advanced delivery technologies with innovative therapeutic approaches. While the active ingredient in a drug is crucial, the method of delivery can significantly influence its overall effectiveness. By combining INNA-051 with a reliable and well-designed nasal delivery system, the partnership aims to maximize the potential benefits of the therapy.
According to Alex Theodorakis, President of Aptar Pharma Prescription, the company is proud to support ENA Respiratory in the clinical development of INNA-051. He emphasized that Aptar Pharma’s expertise extends beyond device manufacturing to include comprehensive technical and regulatory support. This holistic approach helps partners navigate the complexities of drug development and bring innovative therapies closer to market.
The broader context of this collaboration reflects a shift in how respiratory diseases are being addressed. Traditional approaches have largely focused on vaccines and antiviral drugs that target specific pathogens. However, the emergence of new viruses and the variability of existing ones highlight the need for more flexible and broadly applicable solutions.
Host defense enhancers like INNA-051 represent a promising new direction. By stimulating the body’s innate immune response, these therapies could provide a first line of defense against a wide range of viral infections. This virus-agnostic approach is particularly valuable in situations where the exact pathogen may not be known or where multiple viruses are circulating simultaneously.
Intranasal delivery is especially well suited for such therapies, as the nasal cavity is often the primary entry point for respiratory viruses. Delivering a treatment directly to this site can help activate local immune responses quickly, potentially reducing viral replication and transmission.
As the Phase II study progresses, researchers will be closely monitoring outcomes to determine whether INNA-051 can deliver on its promise. Positive results could pave the way for further clinical development and eventual commercialization, offering a new tool in the fight against respiratory infections.
In conclusion, the use of Aptar Pharma’s UDS powder nasal delivery system in ENA Respiratory’s Phase II study of INNA-051 highlights the critical role of innovative delivery technologies in modern drug development. By enabling precise, consistent, and user-friendly administration of a stable powder formulation, the UDS system supports the evaluation of a novel, non-vaccine approach to respiratory disease prevention. This collaboration not only advances the development of INNA-051 but also exemplifies how partnerships between technology providers and pharmaceutical innovators can drive progress in addressing unmet medical needs.
About Aptar
Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries
About ENA Respiratory
ENA Respiratory is a clinical-stage pharmaceutical company tackling respiratory viral infections through the development of host defence enhancers which locally prime and boost the body’s natural first line of defence against invading pathogens. Being virus-agnostic, ENA’s approach offers a solution to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist
